CD274 and hepatocellular carcinoma: Treatment of SB-HCC tumor bearing mice with a reduced dosage of anti-PD-L1 ICI (100μg/mouse/injection instead of 200μg/mouse/per injection) in order to accentuate any combinatorial therapeutic effects, generated some long-term survivors (Fig. 7C).